Neoadjuvant Therapy in Breast Cancer by Angela Lewis Traylor et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Neoadjuvant Therapy in Breast Cancer  
Angela Lewis Traylor1, Nathalie Johnson1 and Esther Han2 
1Legacy Medical Group – Surgical Oncology, Legacy Cancer Services, Portland, Oregon 
2Oregon Health and Sciences University, Department of Surgery 
Sam Jackson Parkway, Portland, Oregon 
USA 
1. Introduction 
This is an exciting time we live in. As technology has advanced at lightning speed, so has 
molecular science and knowledge. With the mapping of the genome, a transformation in 
medical science has followed. Translational application of bench research to the bedside has 
blossomed also at an unprecedented pace. There are many new targeted agents on the 
horizon and future discoveries seem limitless. Although we have advanced in technology, in 
many ways we have not significantly changed our therapeutic treatment approach in breast 
cancer. The pattern of surgery first and adjuvant therapy next remains mainstream. This 
chapter will start by delineating traditional thoughts on systemic therapy prior to surgery as 
it is currently practiced and close with thoughts on where we are headed in the future. 
2. Neoadjuvant chemotherapy  
Historically, neoadjuvant chemotherapy (NCT) has been used in patients with locally 
advanced inoperable disease. More commonly, it is used in patients with operable tumors of 
all stages with promising outcomes. The term “neo” is Greek for new or recent, and 
“adjuvant” originated from Latin, and means to assist or to help. However, neoadjuvant 
chemotherapy is more accurately defined as primary systemic therapy. There are 
advantages afforded by the use of NCT, controversial issues surrounding its use, prognostic 
indicators of response, and some possible disadvantages.  
Several randomized and non-randomized studies have evaluated the efficacy of neoadjuvant 
chemotherapy (Table 1)1. NCT allows “in-vivo” evaluation of tumor biology and an 
assessment of remission rate, complete response to treatment or complete pathologic response 
(cPR), tumor progression, and identification of chemo- resistant tumors. Complete pathologic 
response (cPR) has emerged as a significant predictor of tumor response and may predict long-
term outcomes. Further, NCT allows down staging of tumors by decreasing tumor size and 
extent of tumor mass, thereby facilitating breast conservation therapy (BCT).  
Neoadjuvant chemotherapy was first used in 1973 at the Milan Cancer Institute2,3,4. Their 
goal at the time of the study was to achieve prompt tumor response or shrinkage in locally 
advanced inoperable disease in order to facilitate the delivery of radiation therapy. 
Jacquillat et al. first used NCT for operable breast cancer in 1980 in Paris, France5. Since then 
there have been multiple non-randomized trials demonstrating variable response rates of  
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*Values are median (range).  §Depending on stage at treatment (I-IIIB); #30 per cent had no surgery; § 
includes 33 per cent who had radiotherapy only; ¶ non-responders; **responders. pCR, pathological 
complete response; vinb, vinblastine; thi, thiotepa; met, methotrexate; FU, 5-flourouracil; adr, 
adriamycin; cyc, cyclophosphamide; epi, epirubicin; cis, ciplatin; doc, docetaxel; dox, doxorubicin; vinc, 
vincristine; vino, vinorelbine; tam, tamoxifen; pac, paclitaxel. 
Table 1. Non-Randomized trials of Neoadjuvant Chemotherapy.1 
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large operable and inoperable tumors to NCT. The reported pCR (complete pathologic 
response) rates vary from 3 % to 24 %1. In multiple randomized clinical trials the pCR 
observed varies between 4% and 34 %1. 
The largest prospective randomized trial of NCT was the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-18. This trial showed an overall response rate of 79%, and a 
pCR of 13%6,7. 1493 patients with operable breast cancer were stratified by age, clinical 
tumor size, and clinical nodal status to preoperative versus postoperative administration of 
Adriamycin/cyclophosphamide (AC) q 21 days x four cycles. Patients older than 50 years 
old were also given Tamoxifen 10mg BID x 5 years after completion of chemotherapy. 
Updated results from B-18 continue to demonstrate the significant correlation between pCR 
and DFS. The trial also demonstrated the equivalence between preoperative and 
postoperative chemotherapy. Breast conservation therapy (BCT) rates were 67% versus 60%.  
Another landmark trial, NSABP B-27, enrolled 2411 patients in a randomized prospective 
trial to compare the efficacy of docetaxel in the preoperative versus postoperative setting 
after neoadjuvant AC x four cycles7. The patients were randomized into three groups 
(Figure 1). All patients received Tamoxifen 20mg PO daily x 5 years. 
 
 
Fig. 1.7 
The overall response rate was 91 % for those who received preoperative AC and docetaxel 
vs. 85.7 % for those who received preoperative AC alone (p < 0.001). The pCR was 26 % vs. 
13.7 % (p < 0.001). Preoperative AC-docetaxel also significantly downstaged the axillary 
lymph nodes. 50.7% of the AC- alone group had negative lymph nodes vs. 58.1 % of the AC-
docetaxel group (p< 0.01). Both B-18 and B-27 demonstrate tumor response to NCT as a 
significant predictor of pathologic nodal status.  
Studies on tumor growth and kinetics also support the use of neoadjuvant chemotherapy8. 
Several investigators have demonstrated the inhibitory effect that the “in-situ” or 
undisturbed primary tumor with intact vasculature has on metastatic deposits and the 
development of spontaneous metastases after removal of the primary tumor9,10. In past 
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studies, tumor growth was often measured grossly. However, Gunduz et al. used 
cytokinetic parameters to evaluate tumor growth8. The parameters included: Labeling index, 
primer-dependent DNA polymerase index or growth fraction, DNA synthesis time, and cell 
cycle time. It was shown that following tumor removal changes were observed, specifically, 
accelerated growth in the residual tumor focus within 24hrs. The labeling index and growth 
fraction were increased with a decrease in tumor doubling time. There was minimal change 
in DNA synthesis and cell cycle time. Minimal changes in these last two parameters suggest 
increased growth was not the result of increased DNA synthesis and cell cycle times, but 
increased growth secondary to conversion of non-cycling cells in G0 phase into 
proliferation. Could the intact or “in-situ” primary tumor cause quiescence or down 
regulation of non-cycling cells and thus inhibit metastatic deposits? This is a very interesting 
question that may be answered in future studies on NCT. 
Unfortunately, NCT is not a panacea. There are a small number of patients who will have 
have disease progression while receiving neoadjuvant therapy. In theory, for this group, 
NCT may be delaying delivery of effective surgical treatment to those with chemo-resistant 
tumors. DeLana et al. showed six patients (5.5%) who had disease progression in response 
to induction chemotherapy. However, the percentage of people with disease progression 
remains miniscule in most studies. No patients in Jacquillat’s study had disease 
progression5. In the current era of thinking of breast cancer as a systemic disease, it also begs 
the question as to whether or not nonresponders to NCT are a group of biologically more 
aggressive tumors whose outcome is poor, regardless of pre or post operative therapy. 
NCT may also increase local recurrence rates in those treated with BCT. Mauriac et al. 
demonstrated an initial BCT rate of 63% at 34 months follow-up, which decreased to 45% at 
124 months follow-up1,11. This effect may be partially due to the non-uniform and varied 
response patterns of the primary tumor to NCT (Figure 2)12. 
 
 
Fig. 2.2 
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Examples of the various pathologic responses observed after neoadjuvant chemotherapy. In 
some instances, malignant cells are clustered around a residual nidus after disease response. 
In other cases, residual tumor cells are scattered over the residual volume of disease. A 
breast-conserving surgical procedure directed toward a central nidus may leave different 
volumes of residual disease in these two clinical scenarios. 
NSABP B-18 showed ipsilateral recurrence rates of 10.7% for NCT versus 7.6% for the 
adjuvant chemotherapy group. This discrepancy may be attributable to those mastectomy 
candidates who were converted to BCT candidates after tumor response to NCT. The 
European Organization for Research and Treatment of Cancer (EORTC) 10902 trial showed 
no difference in local recurrence rates between NCT and adjuvant chemotherapy13.  
Although NCT has not yet been shown to improve OS or DFS, it has led to the elucidation of 
pCR as a significant prognostic indicator. Due to the lack of standardization of the definition 
of pCR, a new measure of response has been proposed, called residual cancer burden (RCB) 
14. This is a calculated index that combines tumor size and cellularity with the size and 
number of lymph node metastases. RCB may predict recurrence-free survival and identify a 
group of high-risk patients and those with chemo-resistant tumors. 
Current studies in NCT are looking at ways to predict tumor response to chemotherapy. For 
instance, it is rare that treatment with chemotherapy of a strongly estrogen receptor positive 
( ER + ), progesterone receptor (PR+) ,Her 2 neu negative tumor will result in a cPR. 15 More 
and more studies are evaluating response to chemotherapy based on multiple identified 
subtypes. For instance, lobular cancers ( loss of e-cahedrin expression) may not respond well 
to chemotherapy. Luminal A subtypes (strongly ER+ PR+) tumors often express very low 
growth rate patterns and may also not respond well to chemotherapy. On the other hand, 
ER+PR- ( luminal B ) type tumors and ER-PR-Her2neu- (basal type) tumors respond far 
better to chemotherapy and more often will result in cPR.15.Novel chemotherapeutic agents 
such as the antiangiogenic agent, bevacizumab, and monoclonal antibody, trastuzumab, are 
now being tested in neoadjuvant clinical trials. The future lies in the ability to tailor NCT 
according to predictable prognostic indicators such as tumor subtype , and molecular 
therapeutic markers and in the development of specific NCT regimens with 
individualization based on tumor biology. 
3. Neoadjuvant endocrine therapy 
Systemic chemotherapy (NCT) was first used in the neoadjuvant setting in trials to 
downstage locally advanced tumors. Quite naturally it became the popular treatment 
modality for patients with locally advanced breast cancer considered inoperable or for those 
with operable breast cancer who desired breast conservation therapy. Since the 
development of prognostic markers that can be reliably tested the idea of preoperative 
endocrine therapy based on estrogen and progesterone receptor has also come into question. 
Initial studies of this approach have been most often performed in postmenopausal women.  
A number of clinical trials have compared surgery with primary endocrine therapy in older 
postmenopausal women with large ER+ tumors destined for mastectomy in whom 
neoadjuvant chemotherapy was deemed inappropriate due to age and comorbidities. It was 
clear that many had an initial response to therapy and were able to achieve breast 
conservation but not all. Unfortunately, some experienced disease progression. 
Tamoxifen has for many years been the mainstay of endocrine therapy. Rightfully so, more 
recent trails have compared Tamoxifen to the newer aromatase inhibitors both in the 
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adjuvant and neoadjuvant setting. It is clear from the BIG- I 98 ( letrazole vs Tamoxifen) and 
ATAC (Arimidex vs Tamoxifen Alone or in Combination) trials that aromatase inhibitors 
have slightly superior disease free survival rates (DFS) (about 4-6%) Armed with that 
knowledge, Ingle et al, recently published a series comparing tamoxifen versus letrazole in 
the neoadjuvant setting, and found letrazole had superior clinical response rates.16  
It has, however, become increasingly clear that the strongly ER+PR+HER 2 neu – (luminal 
A tumors) are the ones that respond best to endocrine therapies. Much energy is now 
being spent on looking for markers to predict response to endocrine therapy. Multigene 
prognostic assay tools such as Recurrence Score (Oncotype Dx) and the Amsterdam 70 
gene assay (Mammaprint) define a low risk population and also seem to predict response 
to therapy. Other genomic measurements also hold promise. One is a panel of genes co -
expressed with ESR1 that could predict sensitivity to endocrine therapy (SET) and 
improved relapse free survival.17 Patients with a high SET had few relapses with 
Tamoxifen alone. 
Another measure of response to endocrine therapy is a decrease in Ki-67 with treatment. Ki-
67 is a measure of proliferation and studies are showing that patients who have a decrease 
in expression of Ki-67 after two weeks of endocrine therapy will go on to have a good 
response. The American College of Surgeons – Oncology Group study Z 1031 is looking at 
this measure in post menopausal women with stage 2 or 3 breast cancer be studying it with 
repeat tumor sampling two weeks after start of therapy for ER+ tumors. 
One of the advantages that appear to be offered by neoadjuvant endocrine therapy over 
chemotherapy is concentric shrinkage of the tumor, thereby making it far more likely to 
yield negative margins at the time of surgery. This seems to translate into better local control 
rates with breast conservation therapy and additive radiation. 
3.1 Timing of the sentinel node biopsy in the neoadjuvant setting  
There is controversy on the timing of the sentinel node biopsy in the setting of 
neoadjuvant therapy. Should sentinel node (SNB) evaluation occur before or after 
induction of chemo or endocrine therapy? There are salient points for both sides of this 
controversy. Lymph node status has been and still is a strong predictor of outcome . 
However, cPR after neoadjuvant therapy is also a very strong predictor of outcome, even 
in the setting of positive nodal disease. 
One of the concerns with performing the SNB after neoadjuvant treatment is related to the 
technical ability to find the SNB and its accuracy. Several studies now have demonstrated 
that, in patients who are clinically node negative at diagnosis, the SN can be identified over 
97% of the time with low false negative rates.17,18 Several studies also support the view that 
performing the SNB after NCT allows downstaging of the axilla and results in fewer 
patients being subjected to full axillary node dissection (ALND), with its attendant risk of 
chronic lymphedema. 
Proponents of performing the SNB prior to NCT believe that knowledge of the state of the 
axilla prior to the initiation of chemotherapy is critical for prognostication. In addition, there 
are times that knowledge of the number of lymph nodes involved may influence the 
regimen of chemotherapy delivered or whether radiation is administered after mastectomy. 
In some cases, only one SN is removed for evaluation and post NCT the SNB technique is 
repeated. This particular approach (removing only one SN), however, negates the 
arguments of needing to know number of involved nodes. If only one SN is removed then it 
is unclear if this was the only involved node. After treatment, it is also unclear whether or 
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not nodal disease would have cleared with treatment. The authors do not recommend this 
approach. Instead, if SNB is performed prior to NCT then patients with a positive 
intraoperative SN should proceed with full axillary evaluation (ALND).  
The axilla should be evaluated clinically and if there is any concer, should have axillary 
ultrasound and needle biopsy of suspicious nodes. 
The current recommendation for those with known nodal involvement prior to inception of 
NCT is to proceed with ALND after chemotherapy. 
There are currently trials evaluating the safety of SNB in node positive women who have an 
excellent response to chemotherapy. 
4. The new paradigm 
Clinical research in cancer is resulting in a shift towards a new paradigm. In the past, new 
agents or combinations have been studied in the adjuvant or postoperative setting. The 
tumor has been removed and the only way to measure success or failure of a treatment is to 
wait years to document treatment failures. Any studies that were performed prior to tumor 
extirpation required that all patients, regardless of tumor response, were to receive the same 
chemotherapeutic drugs. Recently, there has been recognition that performing drug studies 
prior to removal of the tumor provides instant feed back on response to therapy.  
Tumor regression in response to therapy can be gauged by examination of the tumor. In 
addition, the treatment plan can be altered based on which drugs are eliciting tumor response.  
The best example of this new change in trial design and concept is seen in the I-SPY 2 trial 
(Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And 
moLecular analysis). On this study patients are randomized to standard NCT or 
investigational drugs with imaging and repeat core biopsies to restudy the tumor molecular 
changes as treatment progresses. The investigational drugs given in the neoadjuvant setting 
allows immediate feedback on drug efficacy by measuring tumor response to treatment. 
This we believe will be the future of cancer clinical trials and will allow us to move forward 
much more quickly with studies of drug efficacy alone or in combination.  
It’s a brave new world! 
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